Chemotherapy Extravasation — Part 1: Agent Classification, Risk Factors, and Prevention

1. Introduction to Agent Classification

The tissue damage potential of antineoplastic agents following extravasation is the primary determinant of clinical urgency, management approach, and patient outcome. International expert panels and professional societies classify intravenous chemotherapy agents into three categories based on their capacity to cause local tissue injury when they escape the vascular compartment.¹²³

1.1 Definitions

Vesicant agents are drugs capable of causing tissue necrosis, blistering, and severe tissue destruction when they infiltrate into subcutaneous or surrounding tissues. Vesicant extravasation, if untreated, can lead to progressive ulceration, deep tissue damage involving tendons and nerves, functional impairment, and in severe cases, may necessitate surgical intervention including debridement, skin grafting, or amputation. Vesicants are further subdivided into:

• DNA-binding vesicants: Agents that intercalate into DNA and cause progressive, delayed tissue destruction that may worsen over days to weeks even without continued drug exposure. These agents are not neutralized by local tissue metabolism and cause cumulative injury.
• Non-DNA-binding vesicants: Agents that cause immediate cellular damage primarily through cytotoxic mechanisms that do not involve DNA binding. Tissue injury from these agents tends to be more limited and may resolve with appropriate conservative management.

Irritant agents are drugs that cause local inflammation, pain, or phlebitis at the infusion site or along the vein but typically do not cause tissue necrosis or ulceration when small volumes extravasate. However, large-volume extravasation of irritant agents can occasionally produce tissue damage resembling that of vesicants.¹

Non-vesicant (neutral) agents are drugs that generally do not cause significant local tissue injury when they extravasate. These agents are typically absorbed and cleared from the tissue without lasting damage, although local discomfort and transient irritation may occur.

2. Complete Classification of Antineoplastic Agents

The following tables represent a consensus synthesis of drug classifications from multiple guideline committees and expert panels.¹²³⁴ Where classification disagreements exist among sources, the more conservative (higher-risk) classification is adopted. Clinicians should verify the classification of any agent against their institutional formulary and the most current prescribing information, as new formulations and concentrations may alter the extravasation risk profile.

2.1 Vesicant Agents — DNA-Binding

2.2 Vesicant Agents — Non-DNA-Binding

2.3 Irritant Agents

2.4 Non-Vesicant (Neutral) Agents

2.5 Special Classification Considerations

Concentration-dependent classification: Several agents may shift from irritant to vesicant behavior depending on concentration:

Antibody-drug conjugates (ADCs): These agents represent an evolving category. While the antibody component is non-vesicant, the cytotoxic payload released upon extravasation may cause local tissue injury. Institutions should classify ADCs conservatively and monitor infusion sites closely. Emerging data should be reviewed as it becomes available.⁵

3. Risk Factors for Extravasation

The expert panel consensus identifies risk factors in three categories: patient-related, procedure-related, and drug-related.¹⁶⁷

3.1 Patient-Related Risk Factors

3.2 Procedure-Related Risk Factors

3.3 Drug-Related Risk Factors

4. Prevention Strategies

Prevention is the cornerstone of extravasation management. The guidelines committees and expert panels uniformly emphasize that institutional prevention protocols reduce extravasation incidence and improve outcomes.¹²³⁶⁷⁸

4.1 Institutional Protocol Requirements

Every institution that administers antineoplastic agents should maintain a written extravasation prevention and management protocol that includes:

1. A current classification list of all antineoplastic agents on the institutional formulary categorized by vesicant, irritant, and non-vesicant potential
2. Standardized assessment criteria for selecting the appropriate vascular access device
3. Procedures for vein assessment and selection
4. Administration guidelines specific to vesicant agents
5. Monitoring frequency and documentation requirements during vesicant infusions
6. A readily accessible extravasation management kit with specific antidotes
7. Step-by-step management instructions for each vesicant class
8. Documentation forms specific to extravasation events
9. Follow-up assessment schedules
10. Reporting and quality improvement processes

4.2 Vein Selection

The selection of an appropriate vein is a critical prevention measure. The following principles are supported by international expert panels and the infusion therapy standards body:⁷⁸

Preferred sites for peripheral vesicant administration:

• Forearm veins (particularly the cephalic and basilic veins in the mid-forearm) are the preferred site for peripheral administration of vesicant agents. These veins are typically well-supported by surrounding tissue, relatively large in caliber, and located away from joints.

Sites to avoid for vesicant administration:

Vein assessment criteria:

• The vein should be palpable, soft, resilient, and refill readily
• Adequate vein caliber relative to the catheter size (choose the smallest catheter appropriate for the infusion)
• Absence of signs of phlebitis, sclerosis, or bruising
• A new venipuncture site should be used for each vesicant administration whenever possible
• If a previous venipuncture attempt has failed, the subsequent successful site should be in a different vein or proximal (not distal) to the failed attempt in the same vein

4.3 Vascular Access Device Selection

Peripheral intravenous catheters:

• Use the smallest gauge catheter that permits adequate flow rate (typically 20–24 gauge)
• Flexible polyurethane or Teflon catheters are preferred over steel (butterfly) needles
• Steel needles should not be used for vesicant administration except for short bolus injections when no alternative is available, per the infusion therapy standards body⁸
• Place the catheter with the tip advancing in the direction of venous blood flow
• Secure the catheter with a transparent dressing that allows continuous visual monitoring of the insertion site
• Newly placed intravenous catheters are preferred for vesicant administration; existing lines that have been in place for more than 24 hours should be assessed carefully for patency

Central venous access devices (CVADs):

The expert panels recommend that central venous access should be considered for patients who:²⁶⁷

• Require multiple cycles of vesicant chemotherapy
• Have poor peripheral venous access
• Require continuous infusion of vesicant agents
• Have risk factors that substantially increase peripheral extravasation risk (see Section 3.1)

Central venous access options include:

Important: Central venous access devices are not risk-free regarding extravasation. Catheter tip malposition, fibrin sheath formation, catheter fracture (pinch-off syndrome), port septum damage from incorrect needles, and catheter disconnection from the port reservoir can all result in extravasation into the mediastinum, pleural space, or subcutaneous tissue of the chest wall. These events can be more dangerous than peripheral extravasation due to larger volumes and delayed detection.²

4.4 Administration Technique for Vesicant Agents

The following technique guidelines are endorsed across multiple expert panels:¹²³⁶⁷⁸

4.4.1 Pre-Administration Assessment

1. Verify the agent classification — confirm whether the drug is a vesicant, irritant, or non-vesicant before beginning the infusion
2. Assess the patient — review risk factors (Section 3.1); evaluate mental status and ability to report symptoms
3. Assess the access site — inspect and palpate the insertion site; assess for signs of infiltration, phlebitis, or compromised site integrity
4. Verify blood return — aspirate for brisk blood return before initiating a vesicant infusion; absence of blood return requires further investigation before proceeding
5. Flush the line — administer 5–10 mL of preservative-free 0.9% sodium chloride to verify patency and assess for pain, swelling, or resistance
6. Confirm free-flowing infusion — ensure the intravenous fluid flows freely by gravity without resistance, swelling, or patient-reported discomfort

4.4.2 During Administration

For peripheral IV push (bolus) vesicant administration:

1. Administer vesicant agents via slow IV push through the side port of a freely running compatible IV infusion
2. Maintain blood return verification every 2–5 mL of drug administered (for agents given by slow push)
3. Observe the infusion site continuously during the injection
4. Instruct the patient to report immediately any pain, burning, stinging, or sensation change at or near the infusion site
5. Flush with 5–10 mL of 0.9% sodium chloride between vesicant agents if multiple drugs are being administered
6. Administer vesicant agents before irritant or non-vesicant agents when given sequentially through a peripheral line (the vein is most intact at the beginning of the infusion)

For peripheral continuous infusion of vesicant agents:

1. Continuous peripheral infusion of vesicant agents should be avoided whenever possible; central venous access is strongly preferred
2. If peripheral infusion is necessary, the infusion rate should be the lowest effective rate
3. Monitor the infusion site at minimum every 30–60 minutes, with more frequent assessment during the first hour
4. Use an infusion pump with pressure-sensing alarms (noting that infusion pumps may continue to infuse even after extravasation has occurred if back-pressure thresholds are not exceeded)
5. Ensure the insertion site is visible and not covered by bedding, clothing, or opaque dressings
6. The patient’s extremity should be positioned comfortably to minimize movement at the infusion site

For CVAD vesicant administration:

1. Verify blood return from the CVAD before initiating vesicant infusion
2. If blood return is absent, do not administer vesicant agents until patency is confirmed (consider catheter dye study, catheter exchange over guidewire, or other institutional protocol for evaluating patency)
3. For implanted ports: use only non-coring (Huber) needles of appropriate gauge and length; secure the needle to prevent dislodgment; verify correct needle placement in the port reservoir
4. Assess the port site, tunnel tract, or PICC insertion site and the area overlying the catheter tip for swelling, erythema, or patient-reported discomfort during infusion
5. Monitor for signs of catheter dysfunction including difficulty flushing, sluggish blood return, or infusion resistance

4.4.3 Post-Administration

1. Flush the catheter with at least 10–20 mL of 0.9% sodium chloride after vesicant administration
2. Document the drug administered, route, site, blood return verification, site assessment findings, and patient tolerance
3. Assess the infusion site before the patient leaves the treatment area
4. Instruct the patient in site monitoring and provide written instructions for when to contact the healthcare team

4.5 Patient Education

Patient education is a preventive measure recognized by all guideline panels.¹⁶ Patients receiving vesicant chemotherapy should be instructed on:

• The importance of reporting any pain, burning, stinging, or discomfort at or near the infusion site immediately
• The importance of keeping the infusion site visible and not placing pressure on the site
• The importance of minimizing movement of the extremity with the infusion catheter
• Signs and symptoms to watch for after discharge, including delayed redness, swelling, blistering, or skin breakdown at the infusion site
• When and how to contact the healthcare team if symptoms develop after leaving the treatment area
• The rationale for why these precautions are necessary

Education should be provided verbally and reinforced with written materials. Comprehension should be assessed, particularly in patients with language barriers, cognitive impairment, or low health literacy.⁶

4.6 Extravasation Kit Requirements

Every area where vesicant chemotherapy is administered should have a readily accessible extravasation management kit. The kit should contain at minimum:¹²³

Note regarding dexrazoxane: Because dexrazoxane requires intravenous administration (not subcutaneous) and must be prepared by pharmacy, it is not typically stocked in the bedside extravasation kit. However, institutions must ensure that dexrazoxane can be obtained and administered within the required time window (ideally within 6 hours of anthracycline extravasation). Pharmacy should be notified immediately when anthracycline extravasation occurs so that dexrazoxane preparation can begin without delay.⁹

5. Special Populations

5.1 Pediatric Patients

Pediatric patients present unique challenges for extravasation prevention:⁶¹⁰

• Smaller vein caliber limits site selection and catheter size options
• Younger children may be unable to articulate symptoms of pain or discomfort
• Patient cooperation may be limited, increasing the risk of catheter dislodgment
• Central venous access is used more frequently in pediatric oncology, but CVAD extravasation can still occur
• Conscious sedation during chemotherapy administration may mask early symptoms
• Play therapists and child life specialists can help prepare children and reduce movement during infusions

Recommendations for pediatric patients:

1. Central venous access is preferred for vesicant administration in pediatric patients whenever clinically appropriate
2. When peripheral access is used, additional measures to secure the catheter and immobilize the extremity should be employed (splinting may be considered)
3. Continuous direct observation by a trained nurse is recommended during peripheral vesicant administration
4. Parent/caregiver education should be provided alongside age-appropriate patient education

5.2 Elderly Patients

Elderly patients are at increased risk due to:⁶

• Fragile, thin-walled veins
• Loss of subcutaneous tissue support
• Impaired wound healing
• Potential cognitive impairment affecting symptom reporting
• Higher prevalence of comorbidities (diabetes, peripheral vascular disease) that affect vascular integrity
• Polypharmacy including anticoagulants

Recommendations for elderly patients:

1. Careful vein assessment with selection of the most robust available vein
2. Smaller-gauge catheters to minimize vein trauma
3. Enhanced monitoring frequency
4. Consider central venous access earlier in treatment course for patients with clearly compromised peripheral vasculature

References